Michael E Menefee Selected Research

pazopanib

1/2020	An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
5/2014	A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
9/2012	A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
1/2012	Systemic therapeutic approaches to advanced thyroid cancers.
10/2010	Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
7/2010	Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael E Menefee Research Topics

Disease

7	Neoplasms (Cancer) 01/2020 - 10/2012
7	Thyroid Neoplasms (Thyroid Cancer) 01/2020 - 10/2010
4	Anaplastic Thyroid Carcinoma 01/2020 - 10/2010
4	Disease Progression 01/2019 - 10/2010
2	medullary Thyroid cancer 10/2017 - 05/2014
2	Hypertension (High Blood Pressure) 05/2014 - 09/2012
2	Fatigue 05/2014 - 10/2010
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2013 - 01/2012
2	Hypopigmentation (Hypomelanosis) 10/2010 - 07/2010
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Papillary Thyroid Cancer 01/2020
1	Hypokalemia 01/2019
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019
1	Adrenocortical Carcinoma 01/2019
1	Diarrhea 05/2014
1	Pain (Aches) 09/2012
1	Nausea 10/2010

Drug/Important Bio-Agent (IBA)

6	pazopanib FDA Link 01/2020 - 07/2010
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2017 - 01/2012
3	Tyrosine Kinase InhibitorsIBA 10/2017 - 07/2010
2	IodineIBA 01/2020 - 01/2020
2	Sorafenib (BAY 43-9006)FDA Link 10/2017 - 01/2012
2	Phosphotransferases (Kinase)IBA 09/2012 - 10/2010
1	Thyroglobulin FDA Link 01/2020
1	GossypolIBA 01/2019
1	TroponinIBA 01/2019
1	gossypol acetic acidIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	veliparibIBA 01/2018
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2018
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2018
1	cabozantinibIBA 10/2017
1	lenvatinibIBA 10/2017
1	temsirolimus FDA Link 01/2013
1	epothilone B (EPO906)IBA 01/2013
1	ixabepilone (BMS 247550)FDA Link 01/2013
1	romidepsin (FK228)FDA Link 10/2012
1	Decitabine FDA Link 10/2012
1	MethyltransferasesIBA 10/2012
1	Axitinib (AG 013736)IBA 01/2012
1	Sunitinib (Sutent)FDA Link 01/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012
1	Tyrosine (L-Tyrosine)FDA Link 10/2010

Therapy/Procedure

5	Therapeutics 01/2020 - 01/2012
2	Salvage Therapy 01/2020 - 10/2017
2	Drug Tapering 09/2012 - 10/2010
1	Radiotherapy 01/2012
1	Drug Therapy (Chemotherapy) 10/2010